Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial

Clifford, Steven, Lannering, Birgitta, Schwalbe, Ed, Hicks, Debbie, O'Toole, Kieran, Nicholson, Sarah, Goschzik, Tobias, zur Mühlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Gustafsson, Göran and Pietsch, Torsten (2015) Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget, 6 (36). pp. 294-302. ISSN 1949-2553

[img]
Preview
Text
5149-73608-1-PB.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
Official URL: http://dx.doi.org/10.18632/oncotarget.5149

Abstract

Purpose: To improve stratification of risk-adapted treatment for non-metastatic (M0), standard-risk medulloblastoma patients by prospective evaluation of biomarkers of reported biological or prognostic significance, alongside clinico-pathological variables, within the multi-center HIT-SIOP-PNET4 trial.

Methods: Formalin-fixed paraffin-embedded tumor tissues were collected from 338 M0 patients (>4.0 years at diagnosis) for pathology review and assessment of the WNT subgroup (MBWNT) and genomic copy-number defects (chromosome 17, MYC/MYCN, 9q22 (PTCH1) and DNA ploidy). Clinical characteristics were reviewed centrally.

Results: The favorable prognosis of MBWNT was confirmed, however better outcomes were observed for non-MBWNT tumors in this clinical risk-defined cohort compared to previous disease-wide clinical trials. Chromosome 17p/q defects were heterogeneous when assessed at the cellular copy-number level, and predicted poor prognosis when they occurred against a diploid (ch17(im)/diploid(cen)), but not polyploid, genetic background. These factors, together with post-surgical tumor residuum (R+) and radiotherapy delay, were supported as independent prognostic markers in multivariate testing. Notably, MYC and MYCN amplification were not associated with adverse outcome. In cross-validated survival models derived for the clinical standard-risk (M0/R0) disease group, (ch17(im)/diploid(cen); 14% of patients) predicted high disease-risk, while the outcomes of patients without (ch17(im)/diploid(cen)) did not differ significantly from MBWNT, allowing re-classification of 86% as favorable-risk.

Conclusion: Biomarkers, established previously in disease-wide studies, behave differently in clinically-defined standard-risk disease. Distinct biomarkers are required to assess disease-risk in this group, and define improved risk-stratification models. Routine testing for specific patterns of chromosome 17 imbalance at the cellular level, and MBWNT, provides a strong basis for incorporation into future trials.

Item Type: Article
Uncontrolled Keywords: medulloblastoma, clinical trial, biomarker, stratification
Subjects: A100 Pre-clinical Medicine
A300 Clinical Medicine
C100 Biology
C400 Genetics
Department: Faculties > Health and Life Sciences > Applied Sciences
Depositing User: Ed Schwalbe
Date Deposited: 14 Oct 2015 15:49
Last Modified: 01 Nov 2017 20:22
URI: http://nrl.northumbria.ac.uk/id/eprint/23849

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics


Policies: NRL Policies | NRL University Deposit Policy | NRL Deposit Licence